DE69636936T2 - Faktor-1, induzierbar durch hypoxämie, und verfahren zur anwendung - Google Patents

Faktor-1, induzierbar durch hypoxämie, und verfahren zur anwendung Download PDF

Info

Publication number
DE69636936T2
DE69636936T2 DE69636936T DE69636936T DE69636936T2 DE 69636936 T2 DE69636936 T2 DE 69636936T2 DE 69636936 T DE69636936 T DE 69636936T DE 69636936 T DE69636936 T DE 69636936T DE 69636936 T2 DE69636936 T2 DE 69636936T2
Authority
DE
Germany
Prior art keywords
hif
polypeptide
nucleotide sequence
nucleotide sequences
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636936T
Other languages
German (de)
English (en)
Other versions
DE69636936D1 (de
Inventor
Gregg L. Towson SEMENZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69636936D1 publication Critical patent/DE69636936D1/de
Publication of DE69636936T2 publication Critical patent/DE69636936T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69636936T 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxämie, und verfahren zur anwendung Expired - Lifetime DE69636936T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US480473 1983-03-29
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1
PCT/US1996/010251 WO1996039426A1 (en) 1995-06-06 1996-06-06 Hypoxia inducible factor-1 and method of use

Publications (2)

Publication Number Publication Date
DE69636936D1 DE69636936D1 (de) 2007-04-12
DE69636936T2 true DE69636936T2 (de) 2007-10-31

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636936T Expired - Lifetime DE69636936T2 (de) 1995-06-06 1996-06-06 Faktor-1, induzierbar durch hypoxämie, und verfahren zur anwendung

Country Status (9)

Country Link
US (3) US5882914A (https=)
EP (2) EP0833840B1 (https=)
JP (2) JPH11507541A (https=)
AT (1) ATE355299T1 (https=)
AU (1) AU704384B2 (https=)
CA (1) CA2222279C (https=)
DE (1) DE69636936T2 (https=)
IL (1) IL118581A (https=)
WO (1) WO1996039426A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
DE69829857T2 (de) * 1997-08-21 2006-02-02 Quark Biotech, Inc., Pleasanton Hypoxie-regulierte gene
AU757930B2 (en) 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
EP1064378A2 (en) * 1998-03-27 2001-01-03 The Board Of Trustees Of The Leland Stanford Junior University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
WO2000076497A1 (en) * 1999-06-14 2000-12-21 Cancer Research Ventures Limited Cancer therapy
WO2001023426A2 (en) * 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
AU2001233937A1 (en) * 2000-02-22 2001-09-03 Oxford Biomedica (Uk) Limited Differential expression screening method
AU9017901A (en) * 2000-08-07 2002-02-18 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the vonhippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
WO2002034291A2 (en) * 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
AU2002302252A1 (en) * 2001-05-23 2002-12-03 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US7700754B1 (en) * 2001-06-05 2010-04-20 Masahiro Hiraoka Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
EP1495120B1 (en) * 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
NZ540779A (en) * 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050014264A1 (en) * 2002-12-11 2005-01-20 University Of Massachusetts Method of introducing siRNA into adipocytes
JP4546454B2 (ja) 2003-01-28 2010-09-15 レクサーン・コーポレイション Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CN100471862C (zh) * 2003-01-31 2009-03-25 雷克珊公司 抑制hif-1表达的反义寡核苷酸
AU2004294950A1 (en) * 2003-11-26 2005-06-16 Entelos, Inc. Treatment of rheumatoid arthritis with Hypoxia-Inducible Factor 1alpha antagonists
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
MX2007005558A (es) * 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
DK2029746T3 (da) * 2006-06-12 2012-10-08 Exegenics Inc D B A Opko Health Inc Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
EP2066791B1 (en) 2006-10-03 2012-09-12 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
NZ598092A (en) * 2008-02-14 2012-07-27 Lincoln University Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
AU2009322279A1 (en) 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms
HRP20250897T1 (hr) 2009-05-02 2025-09-26 Genzyme Corporation Genska terapija za neurodegenerativne poremećaje
WO2011008904A1 (en) 2009-07-17 2011-01-20 Tabor Aaron T Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CA2895791A1 (en) * 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
DK3122375T3 (da) 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69032598T2 (de) * 1989-06-23 1999-03-11 Genentech, Inc., South San Francisco, Calif. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP1806357A1 (en) 2007-07-11
EP0833840A4 (en) 2001-12-19
IL118581A (en) 2000-01-31
WO1996039426A1 (en) 1996-12-12
CA2222279A1 (en) 1996-12-12
EP0833840A1 (en) 1998-04-08
EP0833840B1 (en) 2007-02-28
JP2009077729A (ja) 2009-04-16
US6222018B1 (en) 2001-04-24
ATE355299T1 (de) 2006-03-15
DE69636936D1 (de) 2007-04-12
JPH11507541A (ja) 1999-07-06
IL118581A0 (en) 1996-10-16
US6020462A (en) 2000-02-01
CA2222279C (en) 2011-02-01
AU6332696A (en) 1996-12-24
US5882914A (en) 1999-03-16
AU704384B2 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
DE69636936T2 (de) Faktor-1, induzierbar durch hypoxämie, und verfahren zur anwendung
WO1996039426A9 (en) Hypoxia inducible factor-1 and method of use
DE69534733T2 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
DE69636752T2 (de) Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen
DE69926764T2 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
DE69738370T2 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
DE69531892T2 (de) Fibroblasten-wachstumsfaktor 10
DE69838905T2 (de) Transkriptionsfaktor islet-brain 1 (ib1)
DE69635349T2 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE69837085T2 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE69636072T2 (de) Varianten des p53-proteins und deren therapeutischen verwendungen
DE69530944T2 (de) Keratinozyten-wachstumsfaktor 2
EP0926236A1 (de) Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie
EP1349933A2 (de) Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen
DE69533796T2 (de) Für die glutamatabhängigen chloridkanäle kodierende dna
DE69434997T2 (de) Menschliches Chondromodulin-I-Protein
DE69935414T2 (de) Humanes h-TRCP Protein
DE69434090T2 (de) Epsilon-untereinheit des gaba a-rezeptors
EP0805204B1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
DE69933785T2 (de) Peptide enthaltend eine cholesterin-erkennungssequenz und deren verwendungen
EP1007671B1 (de) Fanconi-gen ii
DE60217081T2 (de) Gen beteiligt an v(d)j rekombination und/oder dna reparatur
DE19725186C2 (de) Herz- und Skelettmuskel-spezifische Nukleinsäure, ihre Herstellung und Verwendung
DE19816894C1 (de) SREBP-2-defiziente Zellinien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition